Ms. Lisa A Fragoso, LMFT Marriage & Family Therapist Medicare: Not Enrolled in Medicare Practice Location: 593 Timbercreek Rd, Pipe Creek, TX 78063 Phone: 210-853-7770 |
News Archive
Affymetrix, Inc., today reported its operating results for the second quarter of 2010. Total revenue for the quarter was $71.7 million, in line with previously announced expectations, as compared to total revenue of $81.6 million in the second quarter of 2009.
In the first study to look at the consequences of anti-gay prejudice for mortality, researchers at Columbia University's Mailman School of Public Health found that lesbian, gay, and bisexual (LGB) individuals who lived in communities with high levels of anti-gay prejudice have a shorter life expectancy of 12 years on average compared with their peers in the least prejudiced communities. "The results of this study suggest a broadening of the consequences of prejudice to include premature death," noted the study's lead author, Mark Hatzenbuehler, PhD, assistant professor of Sociomedical Sciences.
The Monash City Council will decide this week whether to start community consultation on a ban on smoking in alfresco dining areas, shopping strips, and sports clubs. Cr Micaela Drieberg said more public areas would be covered. She added that Eaton Mall in Oakleigh would be one of the areas. She said, "I think people want to be able to enjoy a meal or a coffee or just sitting outside with friends and family, especially as the weather is getting warmer, and not have to be exposed to second-hand smokeā¦ They have just as much right to fresh air as a smoker has the right to smoke in certain places."
YM BioSciences Inc., is presenting posters on its JAK1/2 inhibiting small molecule (CYT387) and on its novel vascular disrupting agent (CYT997) at the Lorne Cancer Conference in Lorne, Victoria, Australia. CYT387 is an oral JAK1/2 inhibitor, originating from the seminal discovery of JAK1 and JAK2 kinases by Dr. Andrew Wilks, the founder of Cytopia Limited, now YM Australia. CYT997 is an orally-available agent with dual mechanisms of vascular disruption and cytotoxicity and has the potential to be broadly active against a range of tumor types.
GZS, Inc., a leader in developing disease-specific and condition-specific Electronic Medical Records/Electronic Health Records and patient registry software solutions, has announced the worldwide release of the WebTracker-Hemophilia EHR patient registry solution used under the new brand name HemaGlobal.
› Verified 2 days ago